Fatigue is one of the harder problems in research. It shows up across many conditions, and it rarely has a single cause. Over the past decade, one thread has held steady in the literature. Much of the work now points to the cell’s energy system.
This overview looks at the peptides and compounds researchers study in the context of fatigue, energy metabolism, and recovery. It is written for practitioners who want the science, not the noise.
Mitochondria are the parts of the cell that make energy, and they're a key factor in this type of research.
They turn fuel into ATP, the molecule the body runs on. When that process slows down, cells have less to work with.
Researchers have found signs of mitochondrial trouble in fatigue-related conditions for years. In myalgic encephalomyelitis and chronic fatigue syndrome (ME/CFS), studies repeatedly report impaired ATP production and mitochondrial dysfunction. The same pattern appears in research on post-viral fatigue. The condition affects an estimated 0.2 to 0.4 percent of the population, and the energy angle keeps drawing attention.
This is why so many of the compounds below share a theme. Each one connects, in some way, to how cells make or protect their energy supply.
Cellular energy and NAD+
NAD+, short for nicotinamide adenine dinucleotide, is a coenzyme found in every cell. It has two main research roles. It shuttles electrons during the reactions that make ATP, and it acts as a substrate for enzymes that manage repair and stress response.
Because NAD+ is central to energy production, it has become a focus of fatigue research. Studies have examined its precursors, the building blocks the body uses to keep NAD+ available. A randomized, placebo-controlled trial studied a combination of CoQ10 and NADH over twelve weeks in ME/CFS participants and reported reductions in fatigue scores compared with placebo. An earlier pilot study of oral NADH in CFS pointed in a similar direction.
The honest read is that the research is promising and still early. Larger, longer studies are needed before anything is settled.
Cellular energy and NAD+
NAD+, short for nicotinamide adenine dinucleotide, is a coenzyme found in every cell. It has two main research roles. It shuttles electrons during the reactions that make ATP, and it acts as a substrate for enzymes that manage repair and stress response.
Because NAD+ is central to energy production, it has become a focus of fatigue research. Studies have examined its precursors, the building blocks the body uses to keep NAD+ available. A randomized, placebo-controlled trial studied a combination of CoQ10 and NADH over twelve weeks in ME/CFS participants and reported reductions in fatigue scores compared with placebo. An earlier pilot study of oral NADH in CFS pointed in a similar direction.
The honest read is that the research is promising and still early. Larger, longer studies are needed before anything is settled.
Mitochondrial protection and SS-31
SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide. Its structure lets it concentrate inside the inner mitochondrial membrane, where it binds cardiolipin. Research links that binding to more stable mitochondrial structure, lower oxidative stress, and supported ATP production.
Most human research on SS-31 has focused on primary mitochondrial disease rather than general fatigue. Results have been mixed. A dose-escalation trial in mitochondrial myopathy showed short-term improvements in a walking test, while a larger later trial did not meet its main goals across the full group. In animal models of aging, SS-31 has been studied for improved ATP and reduced muscle fatigue.
The takeaway is nuanced. SS-31 has a clear mechanism and real clinical history, but its fatigue-specific evidence is strongest in rare mitochondrial conditions, not in broad fatigue.
Want Deeper Insights into Emerging Peptide Research?
Join our newsletter for early insights into emerging blends, research developments, and strategies shaping the future of peptide therapy.